PRCT241220C105000
- 1.53
- -0.84-35.44%
PROCEPT BioRobotics Newsroom
Leerink Partners Sticks to Their Buy Rating for PROCEPT BioRobotics (PRCT)
Jefferies Initiates PROCEPT BioRobotics(PRCT.US) With Hold Rating, Announces Target Price $95
BofA Securities Maintains PROCEPT BioRobotics(PRCT.US) With Buy Rating, Announces Target Price $104
PROCEPT BioRobotics Analyst Ratings
Truist Financial Maintains PROCEPT BioRobotics(PRCT.US) With Buy Rating, Announces Target Price $105
Leerink Partners Maintains PROCEPT BioRobotics(PRCT.US) With Buy Rating, Raises Target Price to $103
A Quick Look at Today's Ratings for PROCEPT BioRobotics(PRCT.US), With a Forecast Between $99 to $103
Strong Financial Performance and Growth Potential Drive Buy Rating for PROCEPT BioRobotics
Analysts Offer Insights on Healthcare Companies: Biohaven Ltd. (BHVN), PROCEPT BioRobotics (PRCT) and Travere Therapeutics (TVTX)
A Quick Look at Today's Ratings for PROCEPT BioRobotics(PRCT.US), With a Forecast Between $75 to $99
PROCEPT BioRobotics Analyst Ratings
TD Cowen Maintains PROCEPT BioRobotics(PRCT.US) With Buy Rating, Maintains Target Price $99
Truist Financial Maintains PROCEPT BioRobotics(PRCT.US) With Buy Rating
Piper Sandler Maintains PROCEPT BioRobotics(PRCT.US) With Buy Rating, Maintains Target Price $75
Piper Sandler Sticks to Its Buy Rating for PROCEPT BioRobotics (PRCT)
PROCEPT BioRobotics Is Maintained at Buy by TD Cowen
PROCEPT BioRobotics Analyst Ratings
TD Cowen Maintains PROCEPT BioRobotics(PRCT.US) With Buy Rating, Raises Target Price to $99
Buy Rating Affirmed for PROCEPT BioRobotics on Hydros Platform Launch and Positive Long-Term Growth Outlook
Truist Financial Maintains PROCEPT BioRobotics(PRCT.US) With Buy Rating, Maintains Target Price $95